Bax/Bak-independent mitochondrial depolarization and reactive oxygen species induction by sorafenib overcome resistance to apoptosis in renal cell carcinoma

Journal of Biological Chemistry

Volumn 292, Issue 16, 2017, Pages 6478-6492

  Gillissen, Bernhard ^a,b   Richter, Anja ^a,b   Richter, Antje ^a   Preissner, Robert ^a   Schulze Osthoff, Klaus ^b,d   Essmann, Frank ^b,d   Daniel, Peter T ^a,b,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DEATH; CELL MEMBRANES; CELLS; CHEMICAL ACTIVATION; CYTOLOGY; DISEASES; PROTEINS;

BCL-2 FAMILY PROTEINS; CANCER THERAPEUTICS; MITOCHONDRIAL APOPTOSIS; MITOCHONDRIAL MEMBRANE POTENTIAL; REACTIVE OXYGEN SPECIES; RENAL CELL CARCINOMA; RESISTANCE MECHANISMS; SIGNALING CASCADES;

MITOCHONDRIA;

CASPASE 8; DEATH RECEPTOR 4; DEATH RECEPTOR 5; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; SORAFENIB; BAK1 PROTEIN, HUMAN; BAX PROTEIN, HUMAN; CARBANILAMIDE DERIVATIVE; CASP8 PROTEIN, HUMAN; MCL1 PROTEIN, HUMAN; NICOTINAMIDE; PROTEIN MCL 1; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTIBODY SPECIFICITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; KIDNEY CARCINOMA; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL MEMBRANE POTENTIAL; OLIGOMERIZATION; OVERALL SURVIVAL; OXIDATIVE PHOSPHORYLATION; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; CARCINOMA, RENAL CELL; DOWN REGULATION; DRUG RESISTANCE; KIDNEY NEOPLASMS; METABOLISM; MITOCHONDRION; PROTEIN CONFORMATION; TUMOR CELL LINE;

APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, RENAL CELL; CASPASE 8; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMANS; KIDNEY NEOPLASMS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN CONFORMATION; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 85018573022     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M116.754184     Document Type: Article

References (58)

1. Falschlehner, C., Ganten, T. M., Koschny, R., Schaefer, U., and Walczak, H. (2009) TRAIL and other TRAIL receptor agonists as novel cancer therapeutics. Adv. Exp. Med. Biol. 647, 195-206
2. Gonzalvez, F., and Ashkenazi, A. (2010) New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene 29, 4752-4765
3. Yang, A., Wilson, N. S., and Ashkenazi, A. (2010) Proapoptotic DR4 and DR5 signaling in cancer cells: Toward clinical translation. Curr. Opin. Cell Biol. 22, 837-844
4. Chaudhary, P. M., Eby, M., Jasmin, A., Bookwalter, A., Murray, J., and Hood, L. (1997) Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway. Immunity 7, 821-830
5. Kischkel, F. C., Lawrence, D. A., Chuntharapai, A., Schow, P., Kim, K. J., and Ashkenazi, A. (2000) Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12, 611-620
6. Suzuki, Y., Nakabayashi, Y., and Takahashi, R. (2001) Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-Apoptotic effect in Fas-induced cell death. Proc. Natl. Acad. Sci. U.S.A. 98, 8662-8667
7. Green, D. R., and Kroemer, G. (2004) The pathophysiology of mitochondrial cell death. Science 305, 626-629
8. Du, C., Fang, M., Li, Y., Li, L., and Wang, X. (2000) Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102, 33-42
9. Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K. J., Debatin, K. M., Krammer, P. H., and Peter, M. E. (1998) Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17, 1675-1687
10. Jost, P. J., Grabow, S., Gray, D., McKenzie, M. D., Nachbur, U., Huang, D. C., Bouillet, P., Thomas, H. E., Borner, C., Silke, J., Strasser, A., and Kaufmann, T. (2009) XIAP discriminates between type I and type II FASinduced apoptosis. Nature 460, 1035-1039
11. Gillissen, B., Richter, A., Richter, A., Overkamp, T., Essmann, F., Hemmati, P. G., Preissner, R., Belka, C., and Daniel, P. T. (2013) Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent "type I" mode. Cell Death Dis. 4, e643
12. Zou, H., Li, Y., Liu, X., and Wang, X. (1999) An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J. Biol. Chem. 274, 11549-11556
13. Yamada, H., Tada-Oikawa, S., Uchida, A., and Kawanishi, S. (1999) TRAIL causes cleavage of bid by caspase-8 and loss of mitochondrial membrane potential resulting in apoptosis in BJAB cells. Biochem. Biophys. Res. Commun. 265, 130-133
14. Luo, X., Budihardjo, I., Zou, H., Slaughter, C., and Wang, X. (1998) Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94, 481-490
15. Slee, E. A., Keogh, S. A., and Martin, S. J. (2000) Cleavage of BID during cytotoxic drug and UV radiation-induced apoptosis occurs downstream of the point of Bcl-2 action and is catalysed by caspase-3: A potential feedback loop for amplification of apoptosis-Associated mitochondrial cytochrome c release. Cell Death Differ. 7, 556-565
16. Daniel, P. T., Schulze-Osthoff, K., Belka, C., and Göner, D. (2003) Guardians of cell death: The Bcl-2 family proteins. Essays Biochem. 39, 73-88
17. van Delft, M. F., and Huang, D. C. (2006) How the Bcl-2 family of proteins interact to regulate apoptosis. Cell Res. 16, 203-213
18. Bender, T., and Martinou, J. C. (2013) Where killers meet: permeabilization of the outer mitochondrial membrane during apoptosis. Cold Spring Harb. Perspect. Biol. 5, a011106
19. Schmelz, K., Wieder, T., Tamm, I., Möller, A., Essmann, F., Geilen, C. C., Schulze-Osthoff, K., Dörken, B., and Daniel, P. T. (2004) Tumor necrosis factor sensitizes malignant cells to chemotherapeutic drugs via the mitochondrial apoptosis pathway independently of caspase-8 and NF-B. Oncogene 23, 6743-6759
20. Marini, P., Schmid, A., Jendrossek, V., Faltin, H., Daniel, P. T., Budach, W., and Belka, C. (2005) Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer 5, 5
21. Keane, M. M., Rubinstein, Y., Cuello, M., Ettenberg, S. A., Banerjee, P., Nau, M. M., and Lipkowitz, S. (2000) Inhibition of NF-κB activity enhances TRAIL mediated apoptosis in breast cancer cell lines. Breast Cancer Res. Treat. 64, 211-219
22. Brooks, A. D., Jacobsen, K. M., Li, W., Shanker, A., and Sayers, T. J. (2010) Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex. Mol. Cancer Res. 8, 729-738
23. Chen, K. F., Yeh, P. Y., Hsu, C., Hsu, C. H., Lu, Y. S., Hsieh, H. P., Chen, P. J., and Cheng, A. L. (2009) Bortezomib overcomes tumor necrosis factorrelated apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway. J. Biol. Chem. 284, 11121-11133
24. Inoue, S., Mai, A., Dyer, M. J., and Cohen, G. M. (2006) Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligandinduced apoptosis. Cancer Res. 66, 6785-6792
25. Huang, S., and Sinicrope, F. A. (2008) BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res. 68, 2944-2951
26. Mott, J. L., Bronk, S. F., Mesa, R. A., Kaufmann, S. H., and Gores, G. J. (2008) BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis. Mol. Cancer Ther. 7, 2339-2347
27. Huang, S., and Sinicrope, F. A. (2010) Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells. Mol. Cancer Ther. 9, 742-750
28. Chen, K. F., Tai, W. T., Liu, T. H., Huang, H. P., Lin, Y. C., Shiau, C. W., Li, P. K., Chen, P. J., and Cheng, A. L. (2010) Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin. Cancer Res. 16, 5189-5199
29. Ricci, M. S., Kim, S. H., Ogi, K., Plastaras, J. P., Ling, J., Wang, W., Jin, Z., Liu, Y. Y., Dicker, D. T., Chiao, P. J., Flaherty, K. T., Smith, C. D., and El-Deiry, W. S. (2007) Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAILinduced death. Cancer Cell 12, 66-80
30. Abdulghani, J., Allen, J. E., Dicker, D. T., Liu, Y. Y., Goldenberg, D., Smith, C. D., Humphreys, R., and El-Deiry, W. S. (2013) Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis. PLoS ONE 8, e75414
31. Gillissen, B., Wendt, J., Richter, A., Richter, A., Möer, A., Overkamp, T., Gebhardt, N., Preissner, R., Belka, C., Dörken, B., and Daniel, P. T. (2010) Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma. J. Cell Biol. 188, 851-862
32. Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., and Kelley, S. (2006) Discovery and development of sorafenib: A multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 5, 835-844
33. Iyer, R., Fetterly, G., Lugade, A., and Thanavala, Y. (2010) Sorafenib: A clinical and pharmacologic review. Expert Opin. Pharmacother. 11, 1943-1955
34. Kane, R. C., Farrell, A. T., Saber, H., Tang, S., Williams, G., Jee, J. M., Liang, C., Booth, B., Chidambaram, N., Morse, D., Sridhara, R., Garvey, P., Justice, R., and Pazdur, R. (2006) Sorafenib for the treatment of advanced renal cell carcinoma. Clin. Cancer Res. 12, 7271-7278
35. Bracarda, S., Caserta, C., Sordini, L., Rossi, M., Hamzay, A., and Crinò, L. (2007) Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib. Ann. Oncol. 18, vi22-25
36. Hoffmann, J. C., Pappa, A., Krammer, P. H., and Lavrik, I. N. (2009) A new C-Terminal cleavage product of procaspase-8, p30, defines an alternative pathway of procaspase-8 activation. Mol. Cell Biol. 29, 4431-4440
37. Wang, C., and Youle, R. J. (2012) Predominant requirement of Bax for apoptosis in HCT116 cells is determined by Mcl-1s inhibitory effect on Bak. Oncogene 31, 3177-3189
38. Ibrahim, N., Yu, Y., Walsh, W. R., and Yang, J. L. (2012) Molecular targeted therapies for cancer: sorafenib mono-Therapy and its combination with other therapies (review). Oncol. Rep. 27, 1303-1311
39. Berasain, C. (2013) Hepatocellular carcinoma and sorafenib: Too many resistance mechanisms? Gut 62, 1674-1675
40. Chen, K. F., Chen, H. L., Shiau, C. W., Liu, C. Y., Chu, P. Y., Tai, W. T., Ichikawa, K., Chen, P. J., and Cheng, A. L. (2013) Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody. Br. J. Pharmacol. 168, 658-672
41. Nojiri, K., Sugimoto, K., Shiraki, K., Tameda, M., Inagaki, Y., Ogura, S., Kasai, C., Kusagawa, S., Yoneda, M., Yamamoto, N., Takei, Y., Nobori, T., and Ito, M. (2013) Sorafenib and TRAIL have synergistic effect on hepatocellular carcinoma. Int. J. Oncol. 42, 101-108
42. Yang, F., Brown, C., Buettner, R., Hedvat, M., Starr, R., Scuto, A., Schroeder, A., Jensen, M., and Jove, R. (2010) Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3. Mol. Cancer Ther 9, 953-962
43. Oh, S. J., Erb, H. H., Hobisch, A., Santer, F. R., and Culig, Z. (2012) Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways. Endocr. Relat. Cancer 19, 305-319
44. Kuo, Y. C., Lin, W. C., Chiang, I. T., Chang, Y. F., Chen, C. W., Su, S. H., Chen, C. L., and Hwang, J. J. (2012) Sorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-κB expression in vitro and in vivo. Biomed. Pharmacother. 66, 12-20
45. Meng, X. W., Lee, S. H., Dai, H., Loegering, D., Yu, C., Flatten, K., Schneider, P., Dai, N. T., Kumar, S. K., Smith, B. D., Karp, J. E., Adjei, A. A., and Kaufmann, S. H. (2007) Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: A mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J. Biol. Chem. 282, 29831-29846
46. Laukens, B., Jennewein, C., Schenk, B., Vanlangenakker, N., Schier, A., Cristofanon, S., Zobel, K., Deshayes, K., Vucic, D., Jeremias, I., Bertrand, M. J., Vandenabeele, P., and Fulda, S. (2011) Smac mimetic bypasses apoptosis resistance in FADD-or caspase-8-deficient cells by priming for tumor necrosis factor α-induced necroptosis. Neoplasia 13, 971-979
47. Schenk, B., and Fulda, S. (2015) Reactive oxygen species regulate Smac mimetic/TNFα-induced necroptotic signaling and cell death. Oncogene 34, 5796-5806
48. Coriat, R., Nicco, C., Chéreau, C., Mir, O., Alexandre, J., Ropert, S., Weill, B., Chaussade, S., Goldwasser, F., and Batteux, F. (2012) Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo. Mol. Cancer Ther. 11, 2284-2293
49. Park, G. B., Choi, Y., Kim, Y. S., Lee, H. K., Kim, D., and Hur, D. Y. (2014) ROS-mediated JNK/p38-MAPK activation regulates Bax translocation in sorafenib-induced apoptosis of EBV-Transformed B cells. Int. J. Oncol. 44, 977-985
50. Bull, V. H., Rajalingam, K., and Thiede, B. (2012) Sorafenib-induced mitochondrial complex I inactivation and cell death in human neuroblastoma cells. J. Proteome Res. 11, 1609-1620
51. Will, Y., Dykens, J. A., Nadanaciva, S., Hirakawa, B., Jamieson, J., Marroquin, L. D., Hynes, J., Patyna, S., and Jessen, B. A. (2008) Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicol Sci. 106, 153-161
52. Izeradjene, K., Douglas, L., Tillman, D. M., Delaney, A. B., and Houghton, J. A. (2005) Reactive oxygen species regulate caspase activation in tumor necrosis factor-related apoptosis-inducing ligand-resistant human colon carcinoma cell lines. Cancer Res. 65, 7436-7445
53. Perez-Cruz, I., Cárcamo, J. M., and Golde, D. W. (2007) Caspase-8 dependent TRAIL-induced apoptosis in cancer cell lines is inhibited by vitamin C and catalase. Apoptosis 12, 225-234
54. Sturm, I., Stephan, C., Gillissen, B., Siebert, R., Janz, M., Radetzki, S., Jung, K., Loening, S., Dörken, B., and Daniel, P. T. (2006) Loss of the tissuespecific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma. Cell Death Differ. 13, 619-627
55. von Haefen, C., Wieder, T., Essmann, F., Schulze-Osthoff, K., Dörken, B., and Daniel, P. T. (2003) Paclitaxel-induced apoptosis in BJAB cells proceeds via a death receptor-independent, caspases-3/-8-driven mitochondrial amplification loop. Oncogene 22, 2236-2247
56. Gillissen, B., Essmann, F., Hemmati, P. G., Richter, A., Richter, A., Oztop, I., Chinnadurai, G., Dörken, B., and Daniel, P. T. (2007) Mcl-1 determines the Bax dependency of Nbk/Bik-induced apoptosis. J. Cell Biol. 179, 701-715
57. Gillissen, B., Essmann, F., Graupner, V., Stärck, L., Radetzki, S., Dörken, B., Schulze-Osthoff, K., and Daniel, P. T. (2003) Induction of cell death by the BH3-only Bcl-2 homolog Nbk/Bik is mediated by an entirely Bax-dependent mitochondrial pathway. EMBO J. 22, 3580-3590
58. Hemmati, P. G., Möer, A., Gillissen, B., Overkamp, T., Milojkovic, A., Wendt, J., Dörken, B., and Daniel, P. T. (2010) Systematic genetic dissection of p14ARF-mediated mitochondrial cell death signaling reveals a key role for p21CDKN1 and the BH3-only protein Puma/bbc3. J. Mol. Med. 88, 609-622